Program
selexipag
Also written as “Selexipag”, “selexipag (Uptravi)” and “Selexipag Film Coated Tablets (T1)”.
Its studies are mostly in Pulmonary Arterial Hypertension · Hypertension, Pulmonary · Hypertension · Scleroderma, Systemic · Sarcoidosis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 213 open or running | phase 4since Mar 6, 2017 | Apr 2, 2010 | Jan 31, 2027phase 3 · NCT05179876 |
| Humanis Saglık Anonim Sirketi | 20 open or running | phase 1since Apr 10, 2025 | Apr 10, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 9 studies since Apr 2, 2010.
- Jun 2, 2016Phase 1 study in Healthy SubjectsJohnson & Johnson · NCT02791815 · 20 enrolled · France
- Aug 18, 2016Phase 1 study in Healthy SubjectsJohnson & Johnson · NCT02882425 · 19 enrolled
- Mar 6, 2017Phase 4 study in Pulmonary Arterial HypertensionJohnson & Johnson · NCT03078907 · 108 enrolled · United States, Austria, France and more
- Jun 9, 2017Phase 3 study in Pulmonary Arterial HypertensionJohnson & Johnson · NCT03187678 · 20 enrolled · United States, Germany
- Apr 3, 2018Phase 2 study in Pulmonary Arterial HypertensionJohnson & Johnson · NCT03492177 · 63 enrolled · United States, Belarus, Belgium and more
- Apr 6, 2018Phase 1 study in Healthy SubjectsJohnson & Johnson · NCT03496506 · 22 enrolled · Belgium
- Sep 27, 2018Phase 3 study in Chronic Thromboembolic Pulmonary HypertensionJohnson & Johnson · NCT03689244 · 128 enrolled · United States, Argentina, Australia and more
- May 7, 2019Phase 2 study in SarcoidosisJohnson & Johnson · NCT03942211 · 10 enrolled · United States, Belgium, Brazil and more
- Nov 8, 2019Phase 3 study in Hypertension, PulmonaryJohnson & Johnson · NCT04175600 · 138 enrolled · United States, Australia, Belarus and more
- Jun 15, 2020Phase 4 study in Pulmonary Arterial HypertensionJohnson & Johnson · NCT04435782 · 9 enrolled · United States, Argentina, Brazil and more
- Sep 22, 2020Phase 3 study in Hypertension, PulmonaryJohnson & Johnson · NCT04565990 · 43 enrolled · Belarus, India, Korea, Republic of and more
- Dec 17, 2021Phase 3 study in Hypertension, PulmonaryJohnson & Johnson · NCT05179876 · 280 planned · Belarus, Belgium, Bulgaria and more
- Apr 10, 2025Humanis Saglık Anonim Sirketi's first study: phase 1 study in Pulmonary Arterial HypertensionNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT06932198 · 14 enrolled · Jordan
- Jul 3, 2026Phase 1 study in HypertensionHumanis Saglık Anonim Sirketi · NCT07694128 · 30 enrolled · India
Ahead
- Jan 31, 2027Primary completion: phase 3 study in Hypertension, PulmonaryJohnson & Johnson · NCT05179876
TargetBeta
“Prostanoid IP receptor agonist”ChEMBL 37, by rule
Other programs on PTGIR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| treprostinilrule | United Therapeutics | phase 4 | 73 |
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07694128Hypertension · India | 1 | Completed | Humanis Saglık Anonim Sirketi | Jun 16, 2026 | 30 |
| NCT06932198Pulmonary Arterial Hypertension · Jordan | 1 | Completed | Humanis Saglık Anonim Sirketi | Mar 3, 2025 | 14 |
| NCT05179876Hypertension, Pulmonary · Belarus, Belgium, Bulgaria and more | 3 | Recruiting | Johnson & Johnson | Jan 31, 2027 | 280 |
| NCT04565990Hypertension, Pulmonary · Belarus, India, Korea, Republic of and more | 3 | Completed | Johnson & Johnson | Nov 10, 2023 | 43 |
| NCT04435782Pulmonary Arterial Hypertension · United States, Argentina, Brazil and more | 4 | Terminated | Johnson & Johnson | Jul 28, 2023 | 9 |
| NCT04175600Hypertension, Pulmonary · United States, Australia, Belarus and more | 3 | Active, not recruiting | Johnson & Johnson | Oct 11, 2024 | 138 |
| NCT03942211Sarcoidosis · United States, Belgium, Brazil and more | 2 | Terminated | Johnson & Johnson | Apr 19, 2023 | 10 |
| NCT03689244Chronic Thromboembolic Pulmonary Hypertension · United States, Argentina, Australia and more | 3 | Terminated | Johnson & Johnson | Jun 7, 2022 | 128 |
| NCT03496506Healthy Subjects · Belgium | 1 | Completed | Johnson & Johnson | May 10, 2018 | 22 |
| NCT03492177Pulmonary Arterial Hypertension · United States, Belarus, Belgium and more | 2 | Active, not recruiting | Johnson & Johnson | Mar 28, 2022 | 63 |
| NCT03187678Pulmonary Arterial Hypertension · United States, Germany | 3 | Completed | Johnson & Johnson | May 29, 2018 | 20 |
| NCT03078907Pulmonary Arterial Hypertension · United States, Austria, France and more | 4 | Completed | Johnson & Johnson | Feb 10, 2020 | 108 |
| NCT02882425Healthy Subjects | 1 | Completed | Johnson & Johnson | Apr 2015 | 19 |
| NCT02791815Healthy Subjects · France | 1 | Completed | Johnson & Johnson | Sep 2016 | 20 |
| NCT02770222Healthy Subjects | 1 | Completed | Johnson & Johnson | Jul 2016 | 40 |
| NCT02745860Healthy Subjects | 1 | Completed | Johnson & Johnson | Jun 2016 | 20 |
| NCT02558231Pulmonary Arterial Hypertension · United States, Australia, Austria and more | 3 | Completed | Johnson & Johnson | Aug 29, 2019 | 247 |
| NCT02471183Pulmonary Arterial Hypertension · United States | 3 | Completed | Johnson & Johnson | Dec 5, 2016 | 34 |
| NCT02260557Scleroderma, Systemic · France, Germany, United Kingdom | 2 | Completed | Johnson & Johnson | Apr 30, 2015 | 74 |
| NCT02206295Bioequivalence | 1 | Completed | Johnson & Johnson | Dec 2012 | 80 |
| NCT02206204Cardiodynamics · United States | 1 | Completed | Johnson & Johnson | Nov 2012 | 159 |
| NCT01112306Pulmonary Arterial Hypertension · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | Aug 26, 2021 | 709 |
| NCT01106014Pulmonary Arterial Hypertension · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | Apr 1, 2014 | 1,156 |
How it is read
Names in the registry
- “Selexipag”, 13 entries
- “selexipag”, 2 entries
- “selexipag (Uptravi)”, 1 entry
- “Selexipag Film Coated Tablets (T1)”, 1 entry
- “Selexipag Film Coated Tablets (T2)”, 1 entry
Conditions, from the studies’ own filings
- Pulmonary Arterial Hypertension, 9 studies
- Hypertension, Pulmonary, 4 studies
- Hypertension, 1 study
- Scleroderma, Systemic, 1 study
- Sarcoidosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.